

Corporate Wellness Partner Program Commences

Sydney, Australia – 27 November 2015: Medical technology company Medibio Limited (**MEB** or the **Company**) is pleased to provide an update on its announcement of 6 November 2015 (*Medibio's corporate partner signs multinational customer*) and its Corporate Wellness Partner program.

In November this year, Medibio announced that its first Corporate Wellness Partner, Vital Conversations, had reached agreement with its first customer for Medibio's Corporate Stress test. The customer corporation is a leading international professional services company with in excess of 5,000 employees in Australia and 200,000 worldwide.

The agreement initially covers a commercial pilot program involving the corporation's Western Australian staff with roll out, conditional upon the results of the pilot, to begin in Western Australia. Pre-registrations for the pilot program opened last week ahead of a planned staff enrolment day in December with the aim of achieving 50 participants for the commercial pilot. Pre-registrations have already doubled the planned 50 person pilot program and will be closed early at 100 participants.

Medibio is pleased to see such a positive response from staff to its corporate stress test in this first use in the commercial arena. The rapid uptake has surprised both Vital and the customer corporation and provides the first indication of potential demand and uptake for Medibio's stress test.

Vital Conversations has indicated that it has received strong interest from a number of other potential customers which it anticipates converting following its first pilot program. In addition, the Company continues to work with a number of wellness providers who have indicated interest in providing the corporate stress product to their client base. Further updates will be provided once commercial terms have been reached.

Under the agreement with Vital, Medibio will provide data analytics and reporting on a per test basis to Vital Conversations, its customer, and their employees. Revenue net to Medibio is in line with prior guidance of between \$40-60 per staff member per test.

Further Information:		Website: www.medibio.com.au
Medibio Shareholder Enquiries to: Kris Knauer CEO and Director Medibio Limited kris.knauer@medibio.com.au T: +61 (0)411 885 979	Medibio Media Enquiries to: Peter Taylor NWR Communications Peter@nwrcommunications.com.au T: +61 (0)412 036 231	

ABOUT VITAL CONVERSATIONS

Vital Conversations are leaders in the provision of psychological services, with innovative service delivery models that are changing the way psychological wellbeing is approached. They have a diverse client base including clients in private, public and not for profit sectors. Specialist areas include Executive Psychological Services and Preventative Mental Health. This encompasses a broad range of industries, including Health, Legal, Engineering, Property, Immigration, Child Protection, Social Services, and includes consultancy contracts with some of the largest corporates in Western Australia.

Vital Conversations provide a broad range of services including:

- Employee and Executive Psychological Health services
 - Psychological Health Check
 - Resilience Programs
 - Leadership Profiling
 - Executive Coaching
 - Emotional Intelligence
 - Depression, Anxiety & Stress Management Risk Screening & Treatment
- Employee Assistance Program (EAP)
- Consulting
- Training
- Psychological Profiling

ABOUT MEDIBIO'S CORPORATE STRESS PRODUCT

Medibio's Corporate Stress Product comprises the first objective test to measure the level of stress and its impact on health and wellbeing in the workplace. It also includes a series of app (or online) based intervention (or treatment) modules tailored specifically for the employees stress level.

The stress test is based on a series of new algorithms which have been developed to measure the type and degree of deviation of the subject's CHR from normal, and the diagnostic significance of this deviation. Medibio's new algorithms accurately classify individuals into one of three categories based on the impact stress has had on their health and wellbeing:

- **normal to mild:** where no immediate action needed
- **moderate:** the impact of stress is approaching unhealthy levels
- **serious:** stress has had an unhealthy impact and lifestyle changes are recommended

ABOUT MEDIBIO LIMITED

Medibio (ASX: MEB), is a medical technology company developing a new objective test to assist in the diagnosis of depression, other mental health disorders and chronic stress. This test utilizes circadian heart rate variability. The technology is based on the scientific finding that circadian heart rate variability is a sensitive measure for depression and other mental health disorders and chronic stress. The technology consists of a heart monitor that sends ECG recordings wirelessly to the cloud where a proprietary algorithms analyse and delivers a quantifiable measure which can be used by a clinician to assist in diagnosis. The Technology has the potential to be the first FDA Approved objective, evidence based approach to the diagnosis of depression and other mental health disorders. The technology has already benefited from 15 years of laboratory research and Medibio is undertaking a number of pivotal studies to validate its clinical utility. Medibio is not just a traditional Medical Device play with revenue dependent upon FDA certification. It has the only new and credible method for the diagnosis of stress and mental wellbeing which can be easily translated to the workplace stress/wellbeing market, wearable technology, and App market. This stress market can be accessed without regulatory approval. Located in Sydney, NSW, Medibio is listed on the Australian Stock Exchange.